Publication

Oral Contraceptive Use and Breast Cancer Risk: Retrospective and Prospective Analyses From a BRCA1 and BRCA2 Mutation Carrier Cohort Study

EMBRACE, GENEPSO, BCFR, HEBON, kConFab, IBCCS, Schrijver, L. H., Olsson, H., Phillips, K-A., Terry, M. B., Goldgar, D. E., Kast, K., Engel, C., Mooij, T. M., Adlard, J., Barrowdale, D., Davidson, R., Eeles, R., Ellis, S., Evans, D. G., Frost, D., Izatt, L., Porteous, M. E., Side, L. E., Walker, L., Berthet, P., Bonadona, V. E., Leroux, D., Mouret-Fourme, E., Venat-Bouvet, L., Buys, S. S., Southey, M. C., John, E. M., Chung, W. K., Daly, M. B., Bane, A., van Asperen, C. J., Garcia, E. B. G., Mourits, M. J., Roos-Blom, M-J., Friedlander, M. L., McLachlan, S-A., Singer, C. F. & van Leeuwen, F. E., Apr-2018, In : JNCI cancer spectrum. 2, 2, 14 p., pky023.

Research output: Contribution to journalArticleAcademicpeer-review

APA

EMBRACE, GENEPSO, BCFR, HEBON, kConFab, IBCCS, ... van Leeuwen, F. E. (2018). Oral Contraceptive Use and Breast Cancer Risk: Retrospective and Prospective Analyses From a BRCA1 and BRCA2 Mutation Carrier Cohort Study. JNCI cancer spectrum, 2(2), [pky023]. https://doi.org/10.1093/jncics/pky023

Author

EMBRACE ; GENEPSO ; BCFR ; HEBON ; kConFab ; IBCCS ; Schrijver, Lieske H. ; Olsson, Hakan ; Phillips, Kelly-Anne ; Terry, Mary Beth ; Goldgar, David E. ; Kast, Karin ; Engel, Christoph ; Mooij, Thea M. ; Adlard, Julian ; Barrowdale, Daniel ; Davidson, Rosemarie ; Eeles, Ros ; Ellis, Steve ; Evans, D. Gareth ; Frost, Debra ; Izatt, Louise ; Porteous, Mary E. ; Side, Lucy E. ; Walker, Lisa ; Berthet, Pascaline ; Bonadona, Val Erie ; Leroux, Dominique ; Mouret-Fourme, Emmanuelle ; Venat-Bouvet, Laurence ; Buys, Saundra S. ; Southey, Melissa C. ; John, Esther M. ; Chung, Wendy K. ; Daly, Mary B. ; Bane, Anita ; van Asperen, Christi J. ; Garcia, Encarna B. Gomez ; Mourits, M. J. ; Roos-Blom, Marie-Jose ; Friedlander, Michael L. ; McLachlan, Sue-Anne ; Singer, Christian F. ; van Leeuwen, F. E. / Oral Contraceptive Use and Breast Cancer Risk : Retrospective and Prospective Analyses From a BRCA1 and BRCA2 Mutation Carrier Cohort Study. In: JNCI cancer spectrum. 2018 ; Vol. 2, No. 2.

Harvard

EMBRACE, GENEPSO, BCFR, HEBON, kConFab, IBCCS, Schrijver, LH, Olsson, H, Phillips, K-A, Terry, MB, Goldgar, DE, Kast, K, Engel, C, Mooij, TM, Adlard, J, Barrowdale, D, Davidson, R, Eeles, R, Ellis, S, Evans, DG, Frost, D, Izatt, L, Porteous, ME, Side, LE, Walker, L, Berthet, P, Bonadona, VE, Leroux, D, Mouret-Fourme, E, Venat-Bouvet, L, Buys, SS, Southey, MC, John, EM, Chung, WK, Daly, MB, Bane, A, van Asperen, CJ, Garcia, EBG, Mourits, MJ, Roos-Blom, M-J, Friedlander, ML, McLachlan, S-A, Singer, CF & van Leeuwen, FE 2018, 'Oral Contraceptive Use and Breast Cancer Risk: Retrospective and Prospective Analyses From a BRCA1 and BRCA2 Mutation Carrier Cohort Study', JNCI cancer spectrum, vol. 2, no. 2, pky023. https://doi.org/10.1093/jncics/pky023

Standard

Oral Contraceptive Use and Breast Cancer Risk : Retrospective and Prospective Analyses From a BRCA1 and BRCA2 Mutation Carrier Cohort Study. / EMBRACE; GENEPSO; BCFR; HEBON; kConFab; IBCCS; Schrijver, Lieske H.; Olsson, Hakan; Phillips, Kelly-Anne; Terry, Mary Beth; Goldgar, David E.; Kast, Karin; Engel, Christoph; Mooij, Thea M.; Adlard, Julian; Barrowdale, Daniel; Davidson, Rosemarie; Eeles, Ros; Ellis, Steve; Evans, D. Gareth; Frost, Debra; Izatt, Louise; Porteous, Mary E.; Side, Lucy E.; Walker, Lisa; Berthet, Pascaline; Bonadona, Val Erie; Leroux, Dominique; Mouret-Fourme, Emmanuelle; Venat-Bouvet, Laurence; Buys, Saundra S.; Southey, Melissa C.; John, Esther M.; Chung, Wendy K.; Daly, Mary B.; Bane, Anita; van Asperen, Christi J.; Garcia, Encarna B. Gomez; Mourits, M. J.; Roos-Blom, Marie-Jose; Friedlander, Michael L.; McLachlan, Sue-Anne; Singer, Christian F.; van Leeuwen, F. E.

In: JNCI cancer spectrum, Vol. 2, No. 2, pky023, 04.2018.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

EMBRACE, GENEPSO, BCFR, HEBON, kConFab, IBCCS et al. Oral Contraceptive Use and Breast Cancer Risk: Retrospective and Prospective Analyses From a BRCA1 and BRCA2 Mutation Carrier Cohort Study. JNCI cancer spectrum. 2018 Apr;2(2). pky023. https://doi.org/10.1093/jncics/pky023


BibTeX

@article{c3891e3d10a24f2c82d6eff39a1b6f3c,
title = "Oral Contraceptive Use and Breast Cancer Risk: Retrospective and Prospective Analyses From a BRCA1 and BRCA2 Mutation Carrier Cohort Study",
abstract = "Background: For BRCA1 and BRCA2 mutation carriers, the association between oral contraceptive preparation (OCP) use and breast cancer (BC) risk is still unclear.Methods: Breast camcer risk associations were estimated from OCP data on 6030 BRCA1 and 3809 BRCA2 mutation carriers using age-dependent Cox regression, stratified by study and birth cohort. Prospective, left-truncated retrospective and full-cohort retrospective analyses were performed.Results: For BRCA1 mutation carriers, OCP use was not associated with BC risk in prospective analyses (hazard ratio [HR] = 1.08, 95{\%} confidence interval [CI] = 0.75 to 1.56), but in the left-truncated and full-cohort retrospective analyses, risks were increased by 26{\%} (95{\%} CI = 6{\%} to 51{\%}) and 39{\%} (95{\%} CI = 23{\%} to 58{\%}), respectively. For BRCA2 mutation carriers, OCP use was associated with BC risk in prospective analyses (HR = 1.75, 95{\%} CI = 1.03 to 2.97), but retrospective analyses were inconsistent (left-truncated: HR = 1.06, 95{\%} CI = 0.85 to 1.33; full cohort: HR = 1.52, 95{\%} CI = 1.28 to 1.81). There was evidence of increasing risk with duration of use, especially before the first full-term pregnancy (BRCA1: both retrospective analyses, P <.001 and P = .001, respectively; BRCA2: full retrospective analysis, P = .002).Conclusions: Prospective analyses did not show that past use of OCP is associated with an increased BC risk for BRCA1 mutation carriers in young middle-aged women (40-50 years). For BRCA2 mutation carriers, a causal association is also not likely at those ages. Findings between retrospective and prospective analyses were inconsistent and could be due to survival bias or a true association for younger women who were underrepresented in the prospective cohort. Given the uncertain safety of long-term OCP use for BRCA1/2 mutation carriers, indications other than contraception should be avoided and non-hormonal contraceptive methods should be discussed.",
keywords = "OVARIAN-CANCER, WOMEN, CONSORTIUM, PREVENTION, KCONFAB",
author = "EMBRACE and GENEPSO and BCFR and HEBON and kConFab and IBCCS and Schrijver, {Lieske H.} and Hakan Olsson and Kelly-Anne Phillips and Terry, {Mary Beth} and Goldgar, {David E.} and Karin Kast and Christoph Engel and Mooij, {Thea M.} and Julian Adlard and Daniel Barrowdale and Rosemarie Davidson and Ros Eeles and Steve Ellis and Evans, {D. Gareth} and Debra Frost and Louise Izatt and Porteous, {Mary E.} and Side, {Lucy E.} and Lisa Walker and Pascaline Berthet and Bonadona, {Val Erie} and Dominique Leroux and Emmanuelle Mouret-Fourme and Laurence Venat-Bouvet and Buys, {Saundra S.} and Southey, {Melissa C.} and John, {Esther M.} and Chung, {Wendy K.} and Daly, {Mary B.} and Anita Bane and {van Asperen}, {Christi J.} and Garcia, {Encarna B. Gomez} and Mourits, {M. J.} and Marie-Jose Roos-Blom and Friedlander, {Michael L.} and Sue-Anne McLachlan and Singer, {Christian F.} and {van Leeuwen}, {F. E.} and Schmidt, {M. K.} and {de Lange}, {J. L.} and Wijnen, {J. T.} and Mensenkamp, {A. R.} and {van der Pol}, {C. C.} and {van Os}, {T. A. M.} and Blok, {M. J.} and Oosterwijk, {J. C.} and {van der Hout}, {A. H.} and {de Bock}, {G. H.} and S. Siesling",
year = "2018",
month = "4",
doi = "10.1093/jncics/pky023",
language = "English",
volume = "2",
journal = "JNCI cancer spectrum",
issn = "2515-5091",
publisher = "Oxford University Press",
number = "2",

}

RIS

TY - JOUR

T1 - Oral Contraceptive Use and Breast Cancer Risk

T2 - Retrospective and Prospective Analyses From a BRCA1 and BRCA2 Mutation Carrier Cohort Study

AU - EMBRACE

AU - GENEPSO

AU - BCFR

AU - HEBON

AU - kConFab

AU - IBCCS

AU - Schrijver, Lieske H.

AU - Olsson, Hakan

AU - Phillips, Kelly-Anne

AU - Terry, Mary Beth

AU - Goldgar, David E.

AU - Kast, Karin

AU - Engel, Christoph

AU - Mooij, Thea M.

AU - Adlard, Julian

AU - Barrowdale, Daniel

AU - Davidson, Rosemarie

AU - Eeles, Ros

AU - Ellis, Steve

AU - Evans, D. Gareth

AU - Frost, Debra

AU - Izatt, Louise

AU - Porteous, Mary E.

AU - Side, Lucy E.

AU - Walker, Lisa

AU - Berthet, Pascaline

AU - Bonadona, Val Erie

AU - Leroux, Dominique

AU - Mouret-Fourme, Emmanuelle

AU - Venat-Bouvet, Laurence

AU - Buys, Saundra S.

AU - Southey, Melissa C.

AU - John, Esther M.

AU - Chung, Wendy K.

AU - Daly, Mary B.

AU - Bane, Anita

AU - van Asperen, Christi J.

AU - Garcia, Encarna B. Gomez

AU - Mourits, M. J.

AU - Roos-Blom, Marie-Jose

AU - Friedlander, Michael L.

AU - McLachlan, Sue-Anne

AU - Singer, Christian F.

AU - van Leeuwen, F. E.

AU - Schmidt, M. K.

AU - de Lange, J. L.

AU - Wijnen, J. T.

AU - Mensenkamp, A. R.

AU - van der Pol, C. C.

AU - van Os, T. A. M.

AU - Blok, M. J.

AU - Oosterwijk, J. C.

AU - van der Hout, A. H.

AU - de Bock, G. H.

AU - Siesling, S.

PY - 2018/4

Y1 - 2018/4

N2 - Background: For BRCA1 and BRCA2 mutation carriers, the association between oral contraceptive preparation (OCP) use and breast cancer (BC) risk is still unclear.Methods: Breast camcer risk associations were estimated from OCP data on 6030 BRCA1 and 3809 BRCA2 mutation carriers using age-dependent Cox regression, stratified by study and birth cohort. Prospective, left-truncated retrospective and full-cohort retrospective analyses were performed.Results: For BRCA1 mutation carriers, OCP use was not associated with BC risk in prospective analyses (hazard ratio [HR] = 1.08, 95% confidence interval [CI] = 0.75 to 1.56), but in the left-truncated and full-cohort retrospective analyses, risks were increased by 26% (95% CI = 6% to 51%) and 39% (95% CI = 23% to 58%), respectively. For BRCA2 mutation carriers, OCP use was associated with BC risk in prospective analyses (HR = 1.75, 95% CI = 1.03 to 2.97), but retrospective analyses were inconsistent (left-truncated: HR = 1.06, 95% CI = 0.85 to 1.33; full cohort: HR = 1.52, 95% CI = 1.28 to 1.81). There was evidence of increasing risk with duration of use, especially before the first full-term pregnancy (BRCA1: both retrospective analyses, P <.001 and P = .001, respectively; BRCA2: full retrospective analysis, P = .002).Conclusions: Prospective analyses did not show that past use of OCP is associated with an increased BC risk for BRCA1 mutation carriers in young middle-aged women (40-50 years). For BRCA2 mutation carriers, a causal association is also not likely at those ages. Findings between retrospective and prospective analyses were inconsistent and could be due to survival bias or a true association for younger women who were underrepresented in the prospective cohort. Given the uncertain safety of long-term OCP use for BRCA1/2 mutation carriers, indications other than contraception should be avoided and non-hormonal contraceptive methods should be discussed.

AB - Background: For BRCA1 and BRCA2 mutation carriers, the association between oral contraceptive preparation (OCP) use and breast cancer (BC) risk is still unclear.Methods: Breast camcer risk associations were estimated from OCP data on 6030 BRCA1 and 3809 BRCA2 mutation carriers using age-dependent Cox regression, stratified by study and birth cohort. Prospective, left-truncated retrospective and full-cohort retrospective analyses were performed.Results: For BRCA1 mutation carriers, OCP use was not associated with BC risk in prospective analyses (hazard ratio [HR] = 1.08, 95% confidence interval [CI] = 0.75 to 1.56), but in the left-truncated and full-cohort retrospective analyses, risks were increased by 26% (95% CI = 6% to 51%) and 39% (95% CI = 23% to 58%), respectively. For BRCA2 mutation carriers, OCP use was associated with BC risk in prospective analyses (HR = 1.75, 95% CI = 1.03 to 2.97), but retrospective analyses were inconsistent (left-truncated: HR = 1.06, 95% CI = 0.85 to 1.33; full cohort: HR = 1.52, 95% CI = 1.28 to 1.81). There was evidence of increasing risk with duration of use, especially before the first full-term pregnancy (BRCA1: both retrospective analyses, P <.001 and P = .001, respectively; BRCA2: full retrospective analysis, P = .002).Conclusions: Prospective analyses did not show that past use of OCP is associated with an increased BC risk for BRCA1 mutation carriers in young middle-aged women (40-50 years). For BRCA2 mutation carriers, a causal association is also not likely at those ages. Findings between retrospective and prospective analyses were inconsistent and could be due to survival bias or a true association for younger women who were underrepresented in the prospective cohort. Given the uncertain safety of long-term OCP use for BRCA1/2 mutation carriers, indications other than contraception should be avoided and non-hormonal contraceptive methods should be discussed.

KW - OVARIAN-CANCER

KW - WOMEN

KW - CONSORTIUM

KW - PREVENTION

KW - KCONFAB

U2 - 10.1093/jncics/pky023

DO - 10.1093/jncics/pky023

M3 - Article

VL - 2

JO - JNCI cancer spectrum

JF - JNCI cancer spectrum

SN - 2515-5091

IS - 2

M1 - pky023

ER -

ID: 120531692